CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 147 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q2 2023. The put-call ratio across all filers is 0.99 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $46,746,718 | -5.7% | 1,377,740 | 0.0% | 0.79% | -13.1% |
| Q1 2023 | $49,571,085 | -24.0% | 1,377,740 | -5.8% | 0.91% | -29.3% |
| Q4 2022 | $65,208,139 | +29.5% | 1,463,050 | -18.3% | 1.29% | +29.8% |
| Q3 2022 | $50,367,000 | +29.2% | 1,791,800 | +23.9% | 0.99% | +18.8% |
| Q2 2022 | $38,976,000 | -20.8% | 1,445,700 | 0.0% | 0.83% | +8.0% |
| Q1 2022 | $49,241,000 | +2.9% | 1,445,700 | +16.7% | 0.77% | +26.1% |
| Q4 2021 | $47,871,000 | -21.4% | 1,238,900 | +9.8% | 0.61% | -23.8% |
| Q3 2021 | $60,901,000 | -13.6% | 1,128,000 | -46.5% | 0.80% | -15.2% |
| Q2 2021 | $70,522,000 | +66.0% | 2,108,908 | +2.3% | 0.95% | +50.3% |
| Q1 2021 | $42,486,000 | +32.0% | 2,062,433 | +12.3% | 0.63% | +27.5% |
| Q4 2020 | $32,186,000 | +328.7% | 1,837,108 | +262.9% | 0.49% | +236.1% |
| Q3 2020 | $7,507,000 | +24.6% | 506,179 | +9.2% | 0.15% | +12.2% |
| Q2 2020 | $6,023,000 | – | 463,335 | – | 0.13% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 1,605,390 | $71,552,232 | 10.98% |
| Octagon Capital Advisors LP | 761,398 | $33,935,509 | 5.28% |
| TSP Capital Management Group, LLC | 269,895 | $12,029,225 | 4.50% |
| Redmile Group, LLC | 1,977,451 | $88,134,991 | 3.60% |
| COMMODORE CAPITAL LP | 495,823 | $22,099 | 3.33% |
| Tri Locum Partners LP | 176,109 | $7,849,000 | 3.18% |
| ACUTA CAPITAL PARTNERS, LLC | 115,000 | $5,125,550 | 3.15% |
| Ikarian Capital, LLC | 267,476 | $11,921,406 | 2.88% |
| RTW INVESTMENTS, LP | 3,084,215 | $137,463,463 | 2.81% |
| Eversept Partners, LP | 558,774 | $24,904,557 | 2.30% |